The global human embryonic stem cells (hESCs) market is anticipated to reach USD 1.06 billion by 2025, according to a new report by Grand View Research, Inc. Application of hESCs as a promising donor source for cellular transplantation therapies is anticipated to bolster progress through to 2025. hESCs technology tends to be useful for tissue engineering in humans due to high histocompatibility between host and graft.
Maintenance of developmental potential for contribution of derivatives of all three germ layers is an important feature of these cells. This ability remains consistent even after clonal derivation or prolonged undifferentiated proliferation, thus pronouncing its accelerated uptake.
In addition, these are capable in expressing high level of alkaline phosphatase, key transcription factors, and telomerase. These factors are found to be of great importance in the maintenance of the inner cellular mass pluripotency.
Furthermore, hESCs can be easily differentiated into defined neurons, neural lineages, oligodendrocytes, and astrocytes. Aforementioned characteristic makes it useful in studying the sequence of events that take place during early neurodevelopment.
However, use of stem cells derived from viable embryos is fraught with ethical issues, prompting scientists to explore other methods to generate ESCs. The other methods include derivation of embryonic germ cells, stem cells from dead embryos, and other techniques.
To request a sample copy or view summary of this report, click the link below:
Further Key Findings from the Report Suggest:
hESC derivation provides a unique opportunity for early human development studies
It is believed to hold a substantial potential for regenerative medicine and biopharma
Differentiated derivatives of these cells are applicable for screening assays in development of novel pharmaceutical moieties
Screening for mutagenic as well as toxic compounds can also be carried out using such derivatives
Presence of lack of suitable donor organs and tissues for regenerative medicine is expected to increase the demand thus influencing growth
Stem cell research is anticipated to exhibit fastest growth amongst the other applications
However, presence of controversies pertaining to their use as a consequence of ethical considerations is responsible for steady growth
Europe accounts for considerable share of the market, following North America
As per a recent survey carried out by Swiss government, citizens there are more willing to accept embryonic stem cell research than politicians
Asia Pacific is anticipated to drive market with fastest YoY growth
Rising awareness amongst the population and physicians with respect to associated therapies is anticipated to propel progress
Key players contributing in this market are CellGenix GmbH, International Stem Cell Corporation, Thermo Fisher Scientific, Inc.; Kite Pharma, PromoCell GmbH, and Lonza
Presence of clinical trial pipeline for embryonic stem cell derived therapy for targeting different diseases is expected to fuel growth.
The diseases targeted include macular degeneration, Parkinson’s disease, type I diabetes mellitus, and spinal cord injury.
Grand View Research has segmented the human embryonic stem cells market on the basis of application and region:
Human Embryonic Stem Cells Application Outlook (Revenue, USD Million, 2014 - 2025)
Stem cell biology research
Human Embryonic Stem Cells Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East and Africa (MEA)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.